Stem definition | Drug id | CAS RN |
---|---|---|
2123 | 51-71-8 |
Dose | Unit | Route |
---|---|---|
60 | mg | O |
Property | Value | Reference |
---|---|---|
S (Water solubility) | 50 mg/mL | Bocci G, Oprea TI, Benet LZ |
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Bocci G, Oprea TI, Benet LZ |
Date | Agency | Company | Orphan |
---|---|---|---|
June 9, 1961 | FDA | PARKE DAVIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Serotonin syndrome | 120.94 | 35.41 | 36 | 1014 | 28646 | 63459326 |
Drug interaction | 78.61 | 35.41 | 48 | 1002 | 229083 | 63258889 |
Product complaint | 44.98 | 35.41 | 14 | 1036 | 12795 | 63475177 |
Hypertensive crisis | 38.55 | 35.41 | 13 | 1037 | 15273 | 63472699 |
Food interaction | 36.61 | 35.41 | 7 | 1043 | 831 | 63487141 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug ineffective | 46.64 | 42.89 | 39 | 355 | 456712 | 34499825 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Serotonin syndrome | 135.79 | 31.66 | 42 | 1074 | 44985 | 79698287 |
Drug interaction | 70.99 | 31.66 | 53 | 1063 | 415130 | 79328142 |
Drug dose titration not performed | 31.66 | 31.66 | 6 | 1110 | 804 | 79742468 |
None
Source | Code | Description |
---|---|---|
ATC | N06AF03 | NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Monoamine oxidase inhibitors, non-selective |
FDA MoA | N0000000184 | Monoamine Oxidase Inhibitors |
MeSH PA | D000928 | Antidepressive Agents |
MeSH PA | D002491 | Central Nervous System Agents |
MeSH PA | D004791 | Enzyme Inhibitors |
MeSH PA | D008996 | Monoamine Oxidase Inhibitors |
MeSH PA | D011619 | Psychotropic Drugs |
FDA EPC | N0000175744 | Monoamine Oxidase Inhibitor |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Depressive disorder | indication | 35489007 | |
Bulimia nervosa | off-label use | 78004001 | |
Suicidal thoughts | contraindication | 6471006 | |
Alcoholism | contraindication | 7200002 | |
Bipolar disorder | contraindication | 13746004 | DOID:3312 |
Feeling agitated | contraindication | 24199005 | |
Orthostatic hypotension | contraindication | 28651003 | |
Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Conduction disorder of the heart | contraindication | 44808001 | |
Low blood pressure | contraindication | 45007003 | |
Chronic heart failure | contraindication | 48447003 | |
Anxiety | contraindication | 48694002 | |
Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
Schizophrenia | contraindication | 58214004 | DOID:5419 |
Cerebrovascular disease | contraindication | 62914000 | DOID:6713 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Kidney disease | contraindication | 90708001 | DOID:557 |
Seizure disorder | contraindication | 128613002 | |
Liver function tests abnormal | contraindication | 166603001 | |
Angina pectoris | contraindication | 194828000 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Hypoglycemic disorder | contraindication | 237630007 | |
Syncope | contraindication | 271594007 | |
Pheochromocytoma | contraindication | 302835009 | |
Myelogram | contraindication | 367401004 | |
Disorder of coronary artery | contraindication | 414024009 | |
Hypertensive Emergencies | contraindication | ||
Severe Headache Disorder | contraindication | ||
Frequent Headache Disorder | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 7.59 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Amine oxidase [flavin-containing] A | Enzyme | INHIBITOR | IC50 | 6.84 | DRUG MATRIX | CHEMBL | |||
Amine oxidase [flavin-containing] B | Enzyme | INHIBITOR | Ki | 7.82 | IUPHAR | CHEMBL | |||
Cytochrome P450 2D6 | Enzyme | IC50 | 6 | DRUG MATRIX | |||||
Cytochrome P450 2C8 | Enzyme | INHIBITOR | Ki | 5.14 | IUPHAR | ||||
Cytochrome P450 2C9 | Enzyme | IC50 | 5.40 | DRUG MATRIX | |||||
Cytochrome P450 2C19 | Enzyme | IC50 | 6.10 | DRUG MATRIX | |||||
Membrane primary amine oxidase | Enzyme | IC50 | 7.70 | CHEMBL | |||||
Indoleamine 2,3-dioxygenase 1 | Enzyme | IC50 | 4.85 | CHEMBL | |||||
Lysine-specific histone demethylase 1A | Enzyme | Ki | 4.75 | CHEMBL | |||||
Cytochrome P450 3A4 | Enzyme | IC50 | 5.70 | DRUG MATRIX | |||||
FAD-linked sulfhydryl oxidase ALR | Enzyme | AC50 | 5.12 | CHEMBL | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.08 | PDSP | |||||
Amine oxidase [flavin-containing] B | Enzyme | IC50 | 7.12 | CHEMBL | |||||
Amine oxidase [flavin-containing] A | Enzyme | IC50 | 7.52 | CHEMBL |
ID | Source |
---|---|
4019886 | VUID |
N0000147971 | NUI |
D00505 | KEGG_DRUG |
156-51-4 | SECONDARY_CAS_RN |
4018632 | VANDF |
4019886 | VANDF |
C0031392 | UMLSCUI |
CHEBI:8060 | CHEBI |
CHEMBL1089 | ChEMBL_ID |
3675 | PUBCHEM_CID |
DB00780 | DRUGBANK_ID |
CHEMBL1200895 | ChEMBL_ID |
D010624 | MESH_DESCRIPTOR_UI |
919 | INN_ID |
7266 | IUPHAR_LIGAND_ID |
O408N561GF | UNII |
8123 | RXNORM |
178818 | MMSL |
5269 | MMSL |
d00883 | MMSL |
001495 | NDDF |
004596 | NDDF |
21614004 | SNOMEDCT_US |
387528000 | SNOMEDCT_US |
9500005 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Nardil | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0071-0350 | TABLET, FILM COATED | 15 mg | ORAL | NDA | 19 sections |
Phenelzine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 40032-360 | TABLET | 15 mg | ORAL | ANDA | 13 sections |
Phenelzine Sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 43386-360 | TABLET | 15 mg | ORAL | ANDA | 15 sections |
phenelzine sulfate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 59762-0119 | TABLET, FILM COATED | 15 mg | ORAL | NDA AUTHORIZED GENERIC | 20 sections |